Graphite Bio Files 8-K for Regulatory Disclosures

TL;DR

Graphite Bio filed an 8-K on 3/8/24 covering Reg FD and financials.

AI Summary

Graphite Bio, Inc. filed an 8-K on March 8, 2024, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Integral Medicines, Inc., is based in South San Francisco, California, and operates in the biological products sector.

Why It Matters

This filing provides important updates and financial information for investors and stakeholders of Graphite Bio, Inc.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K, not indicating any immediate adverse events.

Key Numbers

• 1231 — Fiscal Year End (Indicates the end of the company's fiscal year for financial reporting.)

Key Players & Entities

• Graphite Bio, Inc. (company) — Registrant
• Integral Medicines, Inc. (company) — Former company name
• March 8, 2024 (date) — Date of report
• South San Francisco, California (location) — Principal Executive Offices
• 001-40532 (other) — SEC File Number

FAQ

Key Financial Figures

• $1.03 — idend, which Graphite estimates will be $1.03 per share of Graphite's common stock, w
• $60 m — dend will not exceed an amount equal to $60 million, subject to the adjustments set f

Filing Documents

• d784350d8k.htm (8-K) — 38KB
• d784350dex991.htm (EX-99.1) — 17KB
• 0001193125-24-063785.txt ( ) — 190KB
• grph-20240308.xsd (EX-101.SCH) — 3KB
• grph-20240308_lab.xml (EX-101.LAB) — 18KB
• grph-20240308_pre.xml (EX-101.PRE) — 11KB
• d784350d8k_htm.xml (XML) — 4KB

Forward-Looking Statements

Forward-Looking Statements This communication contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied statements regarding the structure, timing and completion of the proposed merger by and between Graphite and LENZ; the combined company's listing on Nasdaq after the closing of the proposed Merger; expectations regarding the ownership structure of the combined company; the anticipated timing of the closing of the Merger (the "Closing"); the expected executive officers and directors of the combined company; expectations regarding the structure, timing and completion of a concurrent private financing, including investment amounts from investors, timing of closing, expected proceeds and impact on ownership structure; each company's and the combined company's expected cash position at the Closing and cash runway of the combined company following the Merger and private financing; the future operations of the combined company, including commercialization activities, timing of launch and buildout of commercial infrastructure; the nature, strategy and focus of the combined company; the development and commercial potential and potential benefits of any product candidates of the combined company, including expectations around market exclusivity and IP protection; the location of the combined company's corporate headquarters; anticipated clinical drug development activities and related timelines, including the expected timing for announcement of data and other clinical results and potential submission of a New Drug Application for one or more product candidates; and other statements that are not historical fact. All statements other than statements of historical fact contained in this communication are forward-looking statements. These forward-looking statements are made as of the date they were first issued, and were based on the then-cu

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Graphite Bio, Inc. Date: March 8, 2024 By: /s/ Kim Drapkin Kim Drapkin Interim Chief Executive Officer 5

View Full Filing

View this 8-K filing on SEC EDGAR